7.20
-0.1176(-1.61%)
Currency In USD
| Previous Close | 7.32 |
| Open | 7.04 |
| Day High | 7.46 |
| Day Low | 7.04 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 6.2 |
| Volume | 5,485 |
| Average Volume | 14,388 |
| Market Cap | 4.19M |
| PE | -0.63 |
| EPS | -11.5 |
| Moving Average 50 Days | 7.31 |
| Moving Average 200 Days | 428.42 |
| Change | -0.12 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of August 18, 2025 at a share price of $7.2. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.11 as of August 18, 2025 at a share price of $7.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
GlobeNewswire Inc.
Aug 05, 2025 10:00 AM GMT
Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
GlobeNewswire Inc.
Jul 07, 2025 8:01 PM GMT
Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic R
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
GlobeNewswire Inc.
Jun 25, 2025 10:00 AM GMT
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to impr